Bahl & Gaynor Inc. Sells 1,155 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bahl & Gaynor Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,390 shares of the biopharmaceutical company’s stock after selling 1,155 shares during the period. Bahl & Gaynor Inc.’s holdings in Gilead Sciences were worth $1,085,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at $26,000. Tompkins Financial Corp raised its position in shares of Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $29,000. Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $33,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $40,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GILD. Mizuho dropped their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Oppenheimer reissued an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Barclays decreased their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Finally, Royal Bank of Canada reduced their target price on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research note on Friday. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Hold” and a consensus target price of $83.87.

Gilead Sciences Stock Up 0.2 %

Shares of GILD stock opened at $65.42 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The firm’s 50-day moving average is $71.28 and its 200-day moving average is $76.25. The stock has a market cap of $81.45 billion, a price-to-earnings ratio of 181.72, a PEG ratio of 1.17 and a beta of 0.19. Gilead Sciences, Inc. has a 52-week low of $64.63 and a 52-week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. Gilead Sciences’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.37 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 4.2 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.71%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.